Testosterone Drug Maker Clarus Files For Bankruptcy -- Market Talk

Dow Jones2022-09-07

1534 ET - Publicly traded Clarus Therapeutics Holdings, the maker of testosterone drug Jatenzo, has filed for chapter 11 bankruptcy, saying it has missed its sales targets and been unable to meet its debt obligations. Monday's filing in the U.S. Bankruptcy Court in Wilmington, Del., lists $62M in total debts owed to bondholders, trade creditors and others. It has $48.9M in assets. The Northbrook, Ill.-based company says it plans to sell its sole revenue source, Jatenzo, during the proceedings. Private equity firm H.I.G. Capital owns 11% of the company's equity, a court filing says. Because of liquidity constraints and the impact of the pandemic, which halted in-person marketing shortly after Clarus began U.S. commercial sales of Jatenzo in February 2020, revenues have fallen short of targets, Chief Restructuring Officer Lawrence Perkins says (becky.yerak@wsj.com; @beckyyerak)

$(END)$ Dow Jones Newswires

September 06, 2022 15:34 ET (19:34 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2265152600?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-09-07 03:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2265152600","market":"us","top_or_hot":-1,"title":"Testosterone Drug Maker Clarus Files For Bankruptcy -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1534 ET - Publicly traded Clarus Therapeutics Holdings, the maker of testosterone drug Jatenzo, has filed for chapter 11 bankruptcy, saying it has missed its sales targets and been unable to meet its debt obligations. Monday's filing in the U.S. Bankruptcy Court in Wilmington, Del., lists $62M in total debts owed to bondholders, trade creditors and others. It has $48.9M in assets. The Northbrook, Ill.-based company says it plans to sell its sole revenue source, Jatenzo, during the proceedings. Private equity firm H.I.G. Capital owns 11% of the company's equity, a court filing says. Because of liquidity constraints and the impact of the pandemic, which halted in-person marketing shortly after Clarus began U.S. commercial sales of Jatenzo in February 2020, revenues have fallen short of targets, Chief Restructuring Officer Lawrence Perkins says (becky.yerak@wsj.com; @beckyyerak) \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  September 06, 2022 15:34 ET (19:34 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Testosterone Drug Maker Clarus Files For Bankruptcy -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTestosterone Drug Maker Clarus Files For Bankruptcy -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-07 03:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>1534 ET - Publicly traded Clarus Therapeutics Holdings, the maker of testosterone drug Jatenzo, has filed for chapter 11 bankruptcy, saying it has missed its sales targets and been unable to meet its ...</p>\n\n<a href=\"http://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2265152600","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2265152600","pubTimestamp":1662492840,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1534 ET - Publicly traded Clarus Therapeutics Holdings, the maker of testosterone drug Jatenzo, has ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CRXTQ":"Clarus Therapeutics Holdings, Inc.","CRXT":"Clarus Therapeutics Holdings, Inc."},"translate_title":"睾酮药物制造商克拉克鲁斯申请破产--市场传言","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"END":1,"CRXT":0.9,"CRXTQ":0.9},"content_text":"1534 ET - Publicly traded Clarus Therapeutics Holdings, the maker of testosterone drug Jatenzo, has filed for chapter 11 bankruptcy, saying it has missed its sales targets and been unable to meet its debt obligations. Monday's filing in the U.S. Bankruptcy Court in Wilmington, Del., lists $62M in total debts owed to bondholders, trade creditors and others. It has $48.9M in assets. The Northbrook, Ill.-based company says it plans to sell its sole revenue source, Jatenzo, during the proceedings. Private equity firm H.I.G. Capital owns 11% of the company's equity, a court filing says. Because of liquidity constraints and the impact of the pandemic, which halted in-person marketing shortly after Clarus began U.S. commercial sales of Jatenzo in February 2020, revenues have fallen short of targets, Chief Restructuring Officer Lawrence Perkins says (becky.yerak@wsj.com; @beckyyerak) \n\n\n$(END)$ Dow Jones Newswires\n\n\n  September 06, 2022 15:34 ET (19:34 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2265152600"}